ZFIN Image: Li et al., 2021, Figure 8

Image

Figure Caption

Figure 8

Anti-angiogenesis activity of casearlucin A in transgenic zebrafish model. The embryos from transgenic zebrafish Tg (fli1: EGFP) were treated by the tested compound and the anti-angiogenetic compound, sunitinib malate (positive control). DMSO was used as a negative control. After exposure to the compounds for 48 h, the development of intersegmental vessels (ISVs) and dorsal longitudinal anastomotic vessels (DLAVs) were observed, and the length of ISV vessels was measured using ImageJ program. (A) Representative images of zebrafish embryos treated with vehicle, casearlucin A, and sunitinib malate. (B) The average length of ISVs of zebrafish after treated with different concentrations of casearlucin A (5, 10, and 20 μM). (n = 15 for each experimental group). *p < 0.5, ***p < 0.001 versus control group.

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Front Oncol